ARTICLE | Clinical News
Biogen, Eisai's BAN2401 slows AD progression at 18 months
July 20, 2018 4:16 PM UTC
Biogen Inc. (NASDAQ:BIIB) and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary endpoint data on July 5 showing that the highest dose of BAN2401 significantly slowed disease progression and reduced beta amyloid at 18 months in the double-blind Phase II Study 201 to treat Alzheimer's disease.
The trial missed its primary endpoint late last year; however, the partners said they are evaluating next steps for the compound and believe the new data "provide compelling evidence to further support amyloid hypothesis as a therapeutic target."...
BCIQ Target Profiles